Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])

NCT07100730 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT07100730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Phase 3
Overall status
Recruiting
Start date
November 2, 2025
Completion date
November 30, 2027
Enrollment
50 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma (gbm), glioblastoma multiform, glioblastoma multiforme (gbm) who grade iv, glioblastoma multiforme, adult, neoplastic disease